NMR measurements of NMR biomarker GlycA
AssigneeLipoScience, Inc.
InventorsJames D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore
Life of this patent
Estimating the term…
Abstract
Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., μmol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.
Claims8
A method of measuring GlycA, an NMR biomarker derived from a measure of composite NMR signal from carbohydrate portions of acute phase reactant glycoproteins containing N-acetylglucosamine and/or N-acetylgalactosamine moieties, comprising:
- obtaining a composite NMR spectrum of a fitting region of a blood plasma or serum sample of a subject;
- deconvolving the composite NMR spectrum using a defined deconvolution model with a plurality of subclasses of high density lipoprotein (HDL) components, low density lipoprotein (LDL) components, VLDL (very low density lipoprotein)/chylomicron components, and a plurality of curve fit functions associated with at least a GlycA peak region;
- and
- generating a measure of GlycA using the curve fit functions,
- wherein the GlycA NMR biomarker is derived from NMR signal of the protons of N-acetylglucosamine and N-acetylgalactosamine methyl groups, and
- wherein the GlycA peak region is centered at 2.00 ppm and the fitting region extends from 1.845 ppm to 2.080 ppm if the sample is at 47+/−0.2 degrees C. in an NMR spectrometer.
Dependencies are inferred from the claim text.